This study is, to our knowledge, the first investigation of the influence of the coexistence of BRAF and TERT promoter mutations in patients with advanced thyroid carcinoma who require drug therapy, but we found no significant differences between patients with and without these coexisting mutations. The gene discussed is BRAF; the disease is thyroid gland carcinoma.